Stocktoria
ORAMED PHARMACEUTICALS INC. ORMP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2002-04-01
ORAMED PHARMACEUTICALS INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M |
| Gross profit | $13,000 | — | — | — | — |
| R&D expense | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$24.2M |
| Interest expense | — | — | $2.0M | — | — |
| Income tax | $11.3M | $3.2M | — | $100,000 | — |
| Net income | $64.0M | -$19.1M | $5.1M | -$36.6M | -$23.0M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | — |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$21.2M |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$28.4M | -$21.6M |
| Cash & equivalents | $45.9M | $54.4M | $9.1M | $40.5M | $77.2M |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $128.0M |
| Shareholders' equity | $199.7M | $146.3M | $163.8M | $151.8M | $116.5M |
Source: SEC EDGAR filings · CIK 0001176309 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.